1.
ClinicalTrials.gov; 14/02/2022; TrialID: NCT05273255
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05273255
ABSTRACT
Condition:
Cancer;Fecal Microbiota Transplantation;Immune Checkpoint Inhibitors;ImmunotherapyIntervention:
Biological: Fecal Microbiota Transplantation (FMT)Primary outcome:
Change in the intestinal microbiome communityCriteria:
General inclusion criteria for all participants:
- Patients, at minimum 18 years of age, male or female
- Signed informed consent obtained from subject according to local regulations
- ECOG score at the time of study enrolment 0-1
The investigators will include patients/individuals fulfilling inclusion criteria for one
of the following groups:
1. Patients with refractory malignancy (FMT-Recipients). The investigators will recruit
25 individuals with stable or progressing disease after minimum of 1 cycle of CI.
2. Patients with malignancy in remission after ICI therapy (FMT-Donors). The
investigators will recruit 5 patients willing to donate stool samples for the study.
Inclusion criteria FMT-Recipients:
1. Histologically or cytologically confirmed diagnosis of malignancy
2. Currently treated with CI with at least 1 cycle completed. Multiple active
malignancies are allowed.
3. Patient with stable or progressive disease as shown at the most recent staging method
and decided by the treating investigator (based on the radiologic assessment).
4. Must be CI refractory/resistant as judged by the treating physician based on a recent
CT or PET-CT (PET-MRI) scan not older than 8 weeks before screening visit.
5. Willingness to receive FMT administered via colonoscopy and undergo necessary bowel
preparation pre-procedure.
6. Demonstrate adequate organ function as defined below, all screening labs should be
performed within 28 days of FMT intervention.
Following laboratory parameters need to be met:
- Platelet count = 50 x 10^9 / L
- Hemoglobin = 8.5 g/dL
- Prothrombin time (PT)-international normalized ration (INR) = 1.5
7. Female subject of childbearing potential should have a negative urine pregnancy within
minimum 8 hours prior to receiving the study intervention (FMT). If the urine test is
positive or cannot be confirmed as negative, a serum pregnancy test will be required.
8. Female subjects of childbearing potential must be willing to use a clinically
established method of contraception before the FMT procedure.
Inclusion criteria FMT-Donors:
1. Documented history of malignancy treated with ICI therapy.
2. Featuring partial or complete response of the malignancy as assessed by radiologic
examination with a minimum duration of remission lasting =12 months measured since
initiation of therapy.
3. Willingness to complete donor-specific questionnaire.
4. Willingness to complete donor-specific serologic and stool testing to evaluate
infectious agents.
5. Patient tested negatively for all infectious agents specified.
6. Willingness to provide multiple stool samples, until total amount reaches 170g.
7. Absence of major gastrointestinal symptoms 3 months prior to stool donation (including
frequent vomiting, diarrhea, bleeding, constipation).
Exclusion criteria FMT Recipients:
1. Presence of absolute contra-indications to colonoscopy and/or FMT administration:
- Toxic megacolon
- Inflammatory bowel disease
- Anatomic contra-indications to colonoscopy
- Colectomy
2. Patient is currently participating and receiving other study therapy or has
participated in a study of an investigational agent and received study therapy or used
an investigational device within 4 weeks of this study intervention.
3. Currently under any form of systemic antibiotics.
4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (> 10 mg
prednisone daily or equivalent) or any other form of immunosuppressive therapy two
weeks prior to trial treatment. Patients receiving systemic steroids at physiologic
doses are permitted to enroll assuming steroid dose is not above the acceptable
threshold (> 10 mg prednisone daily or equivalent).
5. Severe anaphylactic reaction to any food (food allergies).
6. Had a severe hypersensitivity reaction to propofol.
7. Has serious concomitant illnesses. The eligibility can be granted by the treating
investigator on individual bases.
8. Has HIV infection or AIDS-related illness.
9. Has active infection of HAV, HBV or HCV. Patients with a history of Hepatitis B/C
infection who have received anti-viral therapy and are disease free may be considered
for enrollment after discussion with Principal Investigator.
10. Patient has received a live vaccine within 4 weeks prior to the first dose of
treatment. Seasonal influenza vaccines or COVID-19 vaccines for injection are
generally inactivated virus vaccines and are allowed.
11. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
12. Females who are pregnant or breastfeeding.
13. Active central nervous system (CNS) metastases and/or leptomeningeal involvement.
Exclusion criteria FMT Donors:
1. History or current antibiotic treatment during the 2 month preceding donation.
2. History or current intrinsic gastrointestinal illnesses, including inflammatory bowel
disease, irritable bowel syndrome, chronic diarrheal disorder (e.g. celiac disease or
microscopic colitis) or major gastrointestinal surgical procedures.
3. History or current symptomatic autoimmune illness.
4. History or current documented neurologic or neurodevelopmental disorders.
5. History or current metabolic syndrome, obesity (BMI of >35), or moderate-to-severe
malnutrition (as assessed clinically).
6. History or current infection with HIV (or AIDS-related illness).
7. Positive serological tests for Syphilis, HAV, HBV or HCV.
8. Positive stool test for Escherichia coli, Vancomycin-resistant Enterococcus,
Norovirus, C. difficile, Yersinia, Campylobacter, Shigella or Salmonella.
9. Positive stool test for parasites.
10. Positive Sars-CoV-2 screening/testing (active infection).
Subjects whose pregnancy test on Screening visit shows a positive result, have to be
excluded from the study. All pregnancies occurring during the treatment phase of the study
and within 30 days after discontinuation of study medication have to be reported to the
Investigator-Sponsor within one working day of the investigational sites knowledge of the
pregnancy on the Initial Pregnancy Report Form. Female Subjects should be informed in this
way before signing the informed consent form. Female partners of male participants may get
pregnant without any consequence to the male participant.
2.
biorxiv; 2020.
Preprint
in English
| bioRxiv | ID: ppzbmed-10.1101.2020.12.09.416586
ABSTRACT
Coronavirus disease (COVID-19), caused by SARS-CoV-2, has affected over 65 million individuals and killed over 1.5 million persons (December 8, 2020; www.who.int)1. While fatality rates are higher among the elderly and those with underlying comorbidities2, host factors that promote susceptibility to SARS-CoV-2 infection and severe disease are poorly understood. Although individuals with certain autoimmune/inflammatory disorders show increased susceptibility to viral infections, there is incomplete knowledge of SARS-CoV-2 susceptibility in these diseases.3-7 We report that the autoimmune PTPN2 risk variant rs1893217 promotes expression of the SARS-CoV-2 receptor, ACE2, and increases cellular entry mediated by SARS-CoV-2 spike protein. Elevated ACE2 expression and viral entry were mediated by increased JAK-STAT signalling, and were reversed by the JAK inhibitor, tofacitinib. Collectively, our findings uncover a novel risk biomarker for increased expression of the SARS-CoV-2 receptor and viral entry, and identify a clinically approved therapeutic agent to mitigate this risk.